29 May 2007

Pronota strengthens board with appointment of Chairman

Ghent, Belgium; 29 May 2007 - Pronota nv, the Belgium-based predictive biomarker company, has announced the appointment of Mr John Berriman as Chairman, with immediate effect.

John Berriman is the Chairman of Algeta ASA and a member of the board of directors of MicroMet Inc, Ablynx nv and Oxxon Therapeutics Holdings Inc. Previously, he was a director of Abingworth Management, where he was involved in funding and financing and also served as director of several biotechnology companies in Europe and in the US, many of which obtained listings on public stock exchanges. Prior to that Mr Berriman spent 14 years with Celltech Group. He was on the board of Celltech Group when it listed on the London Stock Exchange in 1994. and whilst at Celltech he founded Celltech Biologics and became the business director of Celltech Therapeutics. He has also served on the boards of Solexa Ltd (director and co-founder), Chroma Therapeutics Ltd (Chairman), Epigenomics AG, Alnylam Inc, and XCounter AB.

John Berriman holds a chemical engineering degree from the University of Cambridge and an MBA from the London Business School.

Commenting on the new appointment, Nick McCooke, chief executive officer of Pronota, said: "I am delighted to announce this appointment. John brings a wealth of experience in the biotechnology sector and this will be invaluable as we introduce Pronota’s technology platforms and products to the market."

Mr Berriman commented: "Pronota is focused on researching and developing protein-based diagnostic and pharmacodiagnostic products. Its advanced technology promises to lead to products which detect, classify and monitor diseases earlier and with greater accuracy than is currently possible and also which distinguish between patients who will and will not respond to a given drug. I am pleased to join the team at this exciting stage of the company’s development."

- ENDS -

Notes to editors:

About Peakadilly (Pronota)

Peakadilly, which changed its name to Pronota in November 2006, was founded in late 2004 to exploit the protein biomarker discovery technology developed at VIB and the University of Ghent. In this short time, it has successfully implemented the technology and won revenue generating projects with big pharma. It applies the technology both to third party projects and to its own projects for developing a new generation of diagnostics and pharmacodiagnostic products.

http://www.pronota.com